|  |
| --- |
| **Oils** |
|  | **Baseline** | **1 month** | **3 months** | **6 months** | **12 months** |  |
| **PROM** | **Mean ± SD** | **Mean ± SD** | **Mean ± SD** | **Mean ± SD** | **Mean ± SD** | **F-value** | **P-value** |
| **GAD-7** | 13.42 | 7.12 | 9.88 | 6.30 | 9.05 | 7.00 | 9.88 | 7.40 | 11.09 | 6.74 | 6.48 | <0.001\*\*\* |
| **SQS** | 3.74 | 2.55 | 5.26 | 2.95 | 5.79 | 2.92 | 5.53 | 2.88 | 5.00 | 2.77 | 6.71 | <0.001\*\*\* |
| **EQ-5D-5L Index** | 0.50 | 0.31 | 0.64 | 0.26 | 0.63 | 0.29 | 0.61 | 0.30 | 0.60 | 0.30 | 7.87 | <0.001\*\*\* |
| **EQ-5D-5L Mobility** | 1.65 | 0.95 | 1.42 | 0.66 | 1.65 | 0.91 | 1.60 | 0.90 | 1.51 | 0.88 | 2.24 | 0.082 |
| **EQ-5D-5L Selfcare** | 1.60 | 0.88 | 1.49 | 0.80 | 1.53 | 0.91 | 1.56 | 0.91 | 1.58 | 0.93 | 0.44 | 0.781 |
| **EQ-5D-5L Usual activities** | 2.44 | 1.12 | 1.88 | 1.07 | 1.91 | 1.09 | 2.12 | 1.01 | 2.14 | 1.08 | 7.60 | <0.001\*\*\* |
| **EQ-5D-5L Pain and discomfort** | 2.35 | 1.13 | 1.93 | 0.91 | 1.98 | 1.10 | 2.09 | 1.13 | 2.12 | 1.14 | 2.97 | 0.031\* |
| **EQ-5D-5L Depression and anxiety** | 3.26 | 1.31 | 2.67 | 1.21 | 2.67 | 1.19 | 2.72 | 1.20 | 2.84 | 1.17 | 5.26 | 0.002\*\* |
| **PGIC** | N/A | N/A | 5.74 | 1.21 | 5.74 | 1.33 | 5.85 | 1.53 | 5.90 | 1.33 | 0.33 | 0.802 |
| **Dried flower** |
| **GAD-7** | 13.57 | 5.53 | 8.59 | 5.88 | 8.86 | 5.89 | 9.20 | 6.13 | 10.59 | 6.38 | 35.78 | <0.001\*\*\* |
| **SQS** | 4.06 | 2.38 | 5.63 | 2.48 | 5.57 | 2.45 | 5.35 | 2.86 | 4.93 | 2.75 | 20.10 | <0.001\*\*\* |
| **EQ-5D-5L Index** | 0.52 | 0.28 | 0.65 | 0.25 | 0.63 | 0.26 | 0.63 | 0.26 | 0.59 | 0.28 | 16.28 | <0.001\*\*\* |
| **EQ-5D-5L Mobility** | 1.57 | 0.88 | 1.51 | 0.85 | 1.50 | 0.88 | 1.51 | 0.84 | 1.53 | 0.88 | 0.65 | 0.628 |
| **EQ-5D-5L Selfcare** | 1.53 | 0.81 | 1.46 | 0.86 | 1.44 | 0.80 | 1.48 | 0.81 | 1.50 | 0.83 | 0.95 | 0.437 |
| **EQ-5D-5L Usual activities** | 2.36 | 1.17 | 2.02 | 0.99 | 2.03 | 1.13 | 2.08 | 1.09 | 2.06 | 1.18 | 8.09 | <0.001\*\*\* |
| **EQ-5D-5L Pain and discomfort** | 2.17 | 1.04 | 1.86 | 0.93 | 1.87 | 0.95 | 1.90 | 0.97 | 1.99 | 1.01 | 8.40 | <0.001\*\*\* |
| **EQ-5D-5L Depression and anxiety** | 3.41 | 1.06 | 2.76 | 1.07 | 2.89 | 1.11 | 2.87 | 1.10 | 3.06 | 1.12 | 18.48 | <0.001\*\*\* |
| **PGIC** | N/A | N/A | 5.50 | 1.43 | 5.70 | 1.20 | 5.64 | 1.24 | 5.76 | 1.28 | 3.24 | 0.024\* |
| **Combination** |
| **GAD-7** | 12.58 | 6.33 | 7.77 | 5.22 | 7.33 | 4.80 | 7.90 | 6.17 | 9.12 | 6.47 | 18.69 | <0.001\*\*\* |
| **SQS** | 4.10 | 2.39 | 5.85 | 2.49 | 5.93 | 2.61 | 5.86 | 2.68 | 5.57 | 2.69 | 17.41 | <0.001\*\*\* |
| **EQ-5D-5L Index** | 0.54 | 0.28 | 0.67 | 0.27 | 0.69 | 0.25 | 0.67 | 0.26 | 0.64 | 0.26 | 10.75 | <0.001\*\*\* |
| **EQ-5D-5L Mobility** | 1.41 | 0.81 | 1.33 | 0.74 | 1.35 | 0.75 | 1.30 | 0.69 | 1.30 | 0.69 | 1.12 | 0.353 |
| **EQ-5D-5L Selfcare** | 1.37 | 0.84 | 1.41 | 0.88 | 1.37 | 0.87 | 1.45 | 0.91 | 1.38 | 0.77 | 0.48 | 0.752 |
| **EQ-5D-5L Usual activities** | 2.30 | 1.32 | 1.91 | 1.08 | 1.76 | 1.01 | 1.89 | 1.11 | 2.05 | 1.20 | 4.76 | 0.002\*\* |
| **EQ-5D-5L Pain and discomfort** | 2.14 | 1.13 | 1.84 | 1.01 | 1.82 | 0.97 | 1.76 | 0.95 | 1.89 | 0.99 | 5.26 | <0.001\*\*\* |
| **EQ-5D-5L Depression and anxiety** | 3.40 | 1.12 | 2.67 | 1.05 | 2.52 | 1.00 | 2.59 | 1.17 | 2.82 | 1.28 | 14.90 | <0.001\*\*\* |
| **PGIC** | N/A | N/A | 5.23 | 1.45 | 5.72 | 1.12 | 5.66 | 1.25 | 5.57 | 1.39 | 8.62 | <0.001\*\*\* |

***Supplementary Table 3. One-way ANOVA comparing patient-reported outcome measures (PROMs) at each time point to baseline for each treatment group.***  *The one-way ANOVA analysis compared the difference in means at each follow up period, relative to baseline and for each treatment type to identify improvements in PROMs over 12 months of treatment with cannabis-based medicinal products. Sample size consistent for all PROMs, n=302, except PGIC, n=264. SD=Standard deviation, GAD-7=Generalised anxiety disorder-7, SQS=Single-item sleep quality scale, PGIC=Patient global impression of change. p<0.050 = \*, p<0.010 = \*\*, p<0.001 = \*\*\*.*